Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Molecules ; 26(9)2021 Apr 29.
Article in English | MEDLINE | ID: mdl-33947062

ABSTRACT

1-Pyrrolines are important intermediates of active natural products, such as the 2,5-dialkyl-1-pyrroline derivatives found in fire ant venoms. Here, 5-hexyl-2-methyl-3,4-dihydro-2H-pyrrole was synthesized by the enzymatic transamination/cyclization of 2,5-undecadione, and enantiodifferenciation was successfully achieved by capillary electrophoresis with sulfobutyl ether-ß-cyclodextrin as the chiral selector. The rationale of the enantiomeric discrimination was based on the results of a docking simulation that revealed the higher affinity of (S)-5-hexyl-2-methyl-3,4-dihydro-2H-pyrrole for the sulfobutyl ether-ß-cyclodextrin.


Subject(s)
Pyrroles/chemistry , beta-Cyclodextrins/chemistry , Chemistry Techniques, Synthetic , Cyclodextrins/chemistry , Electrophoresis, Capillary , Humans , Models, Molecular , Molecular Conformation , Molecular Docking Simulation , Molecular Dynamics Simulation , Molecular Structure , Pyrroles/analysis , Pyrroles/chemical synthesis , beta-Cyclodextrins/analysis
2.
Molecules ; 25(17)2020 Sep 03.
Article in English | MEDLINE | ID: mdl-32899132

ABSTRACT

In the context of the cancer-inflammation relationship and the use of natural products as potential antitumor and anti-inflammatory agents, the alkaloid-enriched fraction of Boehmeriacaudata (BcAEF) aerial parts was evaluated. In vitro antiproliferative studies with human tumor cell lines showed high activity at low concentrations. Further investigation on NCI-H460 cells showed an irreversible effect on cell proliferation, with cell cycle arrest at G2/M phase and programmed cell death induction. Molecular docking studies of four alkaloids identified in BcAEF with colchicine's binding site on ß-tubulin were performed, suggesting (-)-C (15R)-hydroxycryptopleurine as the main inductor of the observed mitotic death. In vivo studies showed that BcAEF was able to reduce Ehrlich tumor volume progression by 30 to 40%. Checking myeloperoxidase activity, BcAEF reduced neutrophils migration towards the tumor. The in vivo anti-inflammatory activity was evaluated by chemically induced edema models. In croton oil-induced ear edema and carrageenan (CG)-induced paw edema models, BcAEF reduced edema around 70 to 80% together with inhibition of activation and/or migration of neutrophils to the inflammatory area. All together the results presented herein show BcAEF as a potent antitumor agent combining antiproliferative and anti-inflammatory properties, which could be further explored in (pre)clinical studies.


Subject(s)
Alkaloids/chemistry , Anti-Inflammatory Agents/pharmacology , Antineoplastic Agents/pharmacology , Boehmeria/chemistry , Computer Simulation , Plant Extracts/pharmacology , Animals , Apoptosis/drug effects , Caspases/metabolism , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Clone Cells , Disease Models, Animal , Ear/pathology , Edema/pathology , Enzyme Activation/drug effects , Exocytosis , Humans , Molecular Docking Simulation , Paclitaxel/pharmacology , Peroxidase/metabolism , Phosphatidylserines/metabolism , Reference Standards , Toxicity Tests, Acute
3.
Biomolecules ; 9(12)2019 12 05.
Article in English | MEDLINE | ID: mdl-31817559

ABSTRACT

Cryptococcus neoformans is an encapsulated yeast responsible for more than 180,000 deaths per year. The standard therapeutic approach against cryptococcosis is a combination of amphotericin B with flucytosine. In countries where cryptococcosis is most prevalent, 5-fluorocytosine is rarely available, and amphotericin B requires intravenous administration. C. neoformans biofilm formation is related to increased drug resistance, which is an important outcome for hospitalized patients. Here, we describe new molecules with anti-cryptococcal activity. A collection of 66 semisynthetic derivatives of ursolic acid and betulinic acid was tested against mature biofilms of C. neoformans at 25 µM. Out of these, eight derivatives including terpenes, benzazoles, flavonoids, and quinolines were able to cause damage and eradicate mature biofilms. Four terpene compounds demonstrated significative growth inhibition of C. neoformans. Our study identified a pentacyclic triterpenoid derived from betulinic acid (LAFIS13) as a potential drug for anti-cryptococcal treatment. This compound appears to be highly active with low toxicity at minimal inhibitory concentration and capable of biofilm eradication.


Subject(s)
Biofilms/drug effects , Cryptococcosis/prevention & control , Cryptococcus neoformans/physiology , Pentacyclic Triterpenes/pharmacology , Cell Line , Cryptococcosis/microbiology , Cryptococcus neoformans/drug effects , Drug Resistance, Fungal/drug effects , Humans , Microbial Sensitivity Tests , Molecular Structure , Pentacyclic Triterpenes/chemistry , Triterpenes/chemistry , Betulinic Acid , Ursolic Acid
4.
Med Chem ; 13(7): 654-663, 2017.
Article in English | MEDLINE | ID: mdl-28545385

ABSTRACT

BACKGROUND: Acetylcholinesterase (AChE) is an important target in the development of drug to treat Alzheimer's disease (AD). In this work, we investigated the effect of twenty-two synthesized chalcones on AChE activity. OBJECTIVE: This work is aimed to synthesize and evaluate the effect of chalcones on the AChE activity, as well as anti-oxidant activity and predict their pharmacokinetic profile. METHOD: Chalcones were synthesized through a Claisen-Schmidt condensation and their inhibitory effect on the AChE was evaluated by the Elmann's colorimetric method. To determine the anti-oxidant activity the DPPH radical scavenging method was chosen. RESULTS: We found that all chalcones inhibit this activity, with IC50 values ranging from 0.008 to 4.8 µM. We selected the most active compound 19 with an IC50 value of 0.008 µM for a kinetic study demonstrating a competitive inhibition mode. Molecular docking simulations showed a good interaction between 19 and the active site of AChE. Considering the prediction of pharmacokinetic parameters being a useful tool for selecting potential drug candidates, our study results suggest that the majority of chalcones, including the most active one, have a promising pharmacokinetic profile and blood-brain barrier permeability. The involvement of reactive oxygen species (ROS) in AD-related events has encouraged us to evaluate these chalcones as radical scavengers. CONCLUSION: We have found that compound 19 is a potent AChE inhibitor, and based on kinetic studies, it acts as a competitive inhibitor.


Subject(s)
Acetylcholinesterase/chemistry , Antioxidants/pharmacokinetics , Chalcones/pharmacokinetics , Cholinesterase Inhibitors/pharmacokinetics , Animals , Antioxidants/chemical synthesis , Antioxidants/chemistry , Antioxidants/metabolism , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/metabolism , Catalytic Domain , Chalcones/chemical synthesis , Chalcones/chemistry , Chalcones/metabolism , Cholinesterase Inhibitors/chemical synthesis , Cholinesterase Inhibitors/chemistry , Cholinesterase Inhibitors/metabolism , Cytochrome P-450 CYP3A/metabolism , Gastrointestinal Absorption/drug effects , Kinetics , Molecular Docking Simulation , Tacrine/pharmacokinetics , Torpedo
5.
Curr Drug Discov Technol ; 14(1): 8-24, 2017.
Article in English | MEDLINE | ID: mdl-27978783

ABSTRACT

BACKGROUND: Guanine phosphoribosyltransferase (GPRT) is a very attractive target for the development of new drugs against G. lamblia because of its critical role in the synthesis of DNA and RNA. Herein we report the use of in silico approaches to identify potential G. lamblia GPRT inhibitors. METHODS: Analyses of the binding site of the enzyme accomplished through the use of several methods allowed the construction of a pharmacophore model, which was screened against a database of commercial substances. The resulting retrieved compounds were then screened against GPRT by consensus docking with two different methods, and the top 10% scored compounds had their poses visually inspected. Root Mean Square Deviation (RMSD) values ≤ 2.0 Å were used to define a consensual pose while RMSD values between 2 and 3 Å defined a partial consensus. Main toxicity endpoints were predicted through substructural analyses. RESULTS: From the 1,230 compounds retrieved in the pharmacophore-based screening, eleven had their binding modes consensually ascribed by the docking methods, suggesting a better selectivity for the parasite enzyme in comparison to the human counterpart by avoiding steric bumps with a flexible loop in the human enzyme binding site. One compound, ZINC38139588, was predicted to be totally devoid of toxicity, being perhaps the most promising of this series. CONCLUSION: Through rigorously validated docking protocols, we predicted the binding mode of these compounds in the GPRT binding site. The use of a consensus docking strategy yielded more reliable predictions of the binding modes to guide the future biological assays.


Subject(s)
Antiparasitic Agents/chemistry , Giardia lamblia/enzymology , Hypoxanthine Phosphoribosyltransferase/antagonists & inhibitors , Molecular Docking Simulation , Protozoan Proteins/antagonists & inhibitors , Binding Sites , Drug Design , Hypoxanthine Phosphoribosyltransferase/chemistry , Protozoan Proteins/chemistry
6.
Curr Med Chem ; 22(11): 1312-23, 2015.
Article in English | MEDLINE | ID: mdl-25620093

ABSTRACT

Imidazoles and benzimidazoles are privileged heterocyclic bioactive compounds used with success in the clinical practice of innumerous diseases. Although there are many advancements in cancer therapy, microtubules remain as one of the few macromolecular targets validated for planning active anti-cancer compounds, and the design of drugs that modulate microtubule dynamics in unknown sites of tubulin is one of the goals of the medicinal chemistry. The discussion of the role of new and commercially available imidazole and benzimidazole derivatives as tubulin modulators is scattered throughout scientific literature, and indicates that these compounds have a tubulin modulation mechanism different from that of tubulin modulators clinically available, such as paclitaxel, docetaxel, vincristine and vinblastine. In fact, recent literature indicates that these derivatives inhibit microtubule formation binding to the colchicine site, present good pharmacokinetic properties and are capable of overcoming multidrug resistance in many cell lines. The understanding of the mechanisms involved in the imidazoles/benzimidazoles modulation of microtubule dynamics is very important to develop new strategies to overcome the resistance to anti-cancer drugs and to discover new biomarkers and targets for cancer chemotherapy.


Subject(s)
Antineoplastic Agents/pharmacology , Benzimidazoles/pharmacology , Imidazoles/pharmacology , Neoplasms/drug therapy , Tubulin Modulators/pharmacology , Tubulin/metabolism , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Benzimidazoles/chemical synthesis , Benzimidazoles/chemistry , Cell Proliferation/drug effects , Humans , Imidazoles/chemical synthesis , Imidazoles/chemistry , Microtubules/drug effects , Microtubules/metabolism , Models, Molecular , Molecular Structure , Neoplasms/pathology , Tubulin Modulators/chemical synthesis , Tubulin Modulators/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...